At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 621 enrolled
Drug / intervention
AMG334 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients
In Brief
A Phase 4 clinical trial evaluating AMG334 and Oral Prophylactic for Episodic Migraine. Completed, enrolled 621 participants across 112 sites in 18 countries.
Detailed Summary
The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpisodic Migraine
CountriesArgentina, Austria, Belgium, Czechia, Finland, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Poland, Portugal, Slovakia, Spain, United Kingdom, United States
CollaboratorsNovartis
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartMay 2019
Primary CompletionOct 2021
Study CompletionSep 2022
TodayJul 2026
First PostedApr 25, 2019
Enrollment StartMay 15, 2019
Primary CompletionOct 1, 2021
Study CompletionSep 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.2 years ago
Interventions
AMG334drug
Subcutaneous Injection
Oral Prophylacticdrug
SOC Oral Tablet/Capsule